Equities researchers at StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
Acorda Therapeutics Stock Down 13.3 %
ACOR stock opened at $0.29 on Monday. The company has a market cap of $6.95 million, a price-to-earnings ratio of -0.03 and a beta of 0.45. The company has a current ratio of 1.86, a quick ratio of 1.49 and a debt-to-equity ratio of 2.10. Acorda Therapeutics has a 12 month low of $0.28 and a 12 month high of $4.99. The firm has a 50-day moving average of $0.42 and a two-hundred day moving average of $0.79.
Get
Acorda Therapeutics alerts:
Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($2.78) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($2.42). The business had revenue of $31.05 million during the quarter. Acorda Therapeutics had a negative net margin of 98.25% and a negative return on equity of 90.29%.
Hedge Funds Weigh In On Acorda Therapeutics
Hedge funds have recently made changes to their positions in the stock. Millennium Management LLC boosted its position in Acorda Therapeutics by 661.2% in the 2nd quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock valued at $145,000 after buying an additional 270,588 shares during the period. Renaissance Technologies LLC boosted its position in Acorda Therapeutics by 27.4% in the 2nd quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock valued at $420,000 after buying an additional 194,100 shares during the period. Virtu Financial LLC purchased a new position in Acorda Therapeutics in the 2nd quarter valued at approximately $68,000. Finally, Prudential Financial Inc. purchased a new position in Acorda Therapeutics in the 2nd quarter valued at approximately $28,000. Hedge funds and other institutional investors own 50.24% of the company's stock.
About Acorda Therapeutics
(Get Rating)
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Further Reading
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
- Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Equities researchers at StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
週一，StockNews.com的股票研究人員在向客户和投資者發佈的一份研究報告中開始報道阿科達治療公司(納斯達克：ACOR-GET Rating)的股票。該經紀公司對這家生物製藥公司的股票設定了“持有”評級。
Acorda Therapeutics Stock Down 13.3 %
ACOR stock opened at $0.29 on Monday. The company has a market cap of $6.95 million, a price-to-earnings ratio of -0.03 and a beta of 0.45. The company has a current ratio of 1.86, a quick ratio of 1.49 and a debt-to-equity ratio of 2.10. Acorda Therapeutics has a 12 month low of $0.28 and a 12 month high of $4.99. The firm has a 50-day moving average of $0.42 and a two-hundred day moving average of $0.79.
雅高股價週一開盤報0.29美元。該公司市值為695萬美元，市盈率為-0.03倍，貝塔係數為0.45。該公司的流動比率為1.86，速動比率為1.49，債務權益比率為2.10。Acorda Treeutics的12個月低點為0.28美元，12個月高位為4.99美元。該公司的50日移動均線切入位在0.42美元，200日移動均線切入位在0.79美元。
Get
Acorda Therapeutics
alerts:
Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($2.78) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($2.42). The business had revenue of $31.05 million during the quarter. Acorda Therapeutics had a negative net margin of 98.25% and a negative return on equity of 90.29%.
阿科達治療公司(納斯達克：ACOR-GET評級)最近一次發佈季度收益數據是在8月4日星期四。這家生物製藥公司公佈了該季度每股收益(2.78美元)，低於分析師普遍預期的(0.36美元)至(2.42美元)。該業務在本季度的收入為3105萬美元。Acorda Treeutics的淨利潤率為負98.25%，股本回報率為負90.29%。
Hedge Funds Weigh In On Acorda Therapeutics
Hedge funds have recently made changes to their positions in the stock. Millennium Management LLC boosted its position in Acorda Therapeutics by 661.2% in the 2nd quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock valued at $145,000 after buying an additional 270,588 shares during the period. Renaissance Technologies LLC boosted its position in Acorda Therapeutics by 27.4% in the 2nd quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock valued at $420,000 after buying an additional 194,100 shares during the period. Virtu Financial LLC purchased a new position in Acorda Therapeutics in the 2nd quarter valued at approximately $68,000. Finally, Prudential Financial Inc. purchased a new position in Acorda Therapeutics in the 2nd quarter valued at approximately $28,000. Hedge funds and other institutional investors own 50.24% of the company's stock.
對衝基金最近對其股票頭寸進行了調整。千禧管理公司在第二季度將其在阿科達治療公司的地位提高了661.2%。Millennium Management LLC現在擁有這家生物製藥公司311,509股票，價值145,000美元，在此期間又購買了270,588股票。復興科技有限責任公司在第二季度將其在Acorda Treateutics的地位提高了27.4%。復興科技有限責任公司現在持有這家生物製藥公司901,318股股票，價值42萬美元，在此期間又購買了194,100股。Virtu Financial LLC在第二季度購買了Acorda治療公司的一個新頭寸，價值約6.8萬美元。最後，保誠金融公司在第二季度購買了Acorda治療公司的一個新頭寸，價值約為2.8萬美元。對衝基金和其他機構投資者持有該公司50.24%的股票。
About Acorda Therapeutics
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Acorda治療公司是一家生物製藥公司，在美國開發和銷售神經疾病的治療方法。該公司在歐洲營銷Ampyra(達法普利定)，一種改善多發性硬化症(MS)患者行走能力的口服藥物；以及Inbrija，用於治療帕金森病的間歇期。
Further Reading
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
- Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- 免費獲取StockNews.com關於Acorda治療公司(ACOR)的研究報告
- 卡特彼勒能否在下跌的市場中走得更高？
- Dave&Buster‘s能免受高通脹和低支出的影響嗎？
- 這三隻表現最好的中型股應該出現在你的觀察名單上嗎？
- 華爾街對Datadog的熱情會帶來巨大的收益嗎？
- MarketBeat：回顧一週9/19-9/23
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Acorda治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Acorda Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
